XNASINBX
Market cap184mUSD
Jan 14, Last price
12.74USD
1D
-6.60%
1Q
-20.62%
IPO
-38.31%
Name
Inhibrx Inc
Chart & Performance
P/E
—
P/S
102.46
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.72%
Rev. gr., 5y
-24.83%
Revenues
2m
-17.36%
Net income
-241m
L+66.20%
CFO
-193m
L+67.66%
Earnings
Feb 26, 2025
Profile
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 1,800 -17.36% | 2,178 -69.43% | ||||||
Cost of revenue | 222,212 | 134,155 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (220,412) | (131,977) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 3 | 3 | ||||||
Tax Rate | ||||||||
NOPAT | (220,415) | (131,980) | ||||||
Net income | (241,361) 66.20% | (145,226) 77.61% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 201,961 | 127,371 | ||||||
BB yield | -11.28% | -12.89% | ||||||
| Debt | ||||||||
Debt current | 4,126 | 1,860 | ||||||
Long-term debt | 211,251 | 207,102 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 3,173 | |||||||
Net debt | (62,547) | (64,903) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (193,309) | (115,301) | ||||||
CAPEX | (4,593) | (686) | ||||||
Cash from investing activities | (4,593) | (686) | ||||||
Cash from financing activities | 201,961 | 258,551 | ||||||
FCF | (222,568) | (129,707) | ||||||
| Balance | ||||||||
Cash | 277,924 | 273,865 | ||||||
Long term investments | ||||||||
Excess cash | 277,834 | 273,756 | ||||||
Stockholders' equity | (613,729) | (372,369) | ||||||
Invested Capital | 869,436 | 637,528 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 47,130 | 40,108 | ||||||
Price | 38.00 54.22% | 24.64 -43.58% | ||||||
Market cap | 1,790,940 81.22% | 988,261 -40.46% | ||||||
EV | 1,728,393 | 923,358 | ||||||
EBITDA | (219,221) | (130,752) | ||||||
EV/EBITDA | ||||||||
Interest | 31,840 | 16,107 | ||||||
Interest/NOPBT | ||||||||